









市场行情
/
股票
/
nasdaq-iron
/

Disc Medicine Inc

IRON

80.330USD

-0.100-0.12%

收盘 12/26, 16:00（美东）报价延迟15分钟

2.81B总市值

亏损市盈率 TTM



Disc Medicine Inc

80.330

-0.100-0.12%

概览公司财务分析

概览

公司

财务

分析

关于 Disc Medicine Inc 公司

Disc Medicine, Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases. The Company's pipeline includes bitopertin for the treatment of erythropoietic porphyrias (Eps), including erythropoietic protoporphyria (EPP) and X-linked protoporphyria (XLP), and Diamond-Blackfan Anemia (DBA); DISC-0974 for the treatment of anemia of myelofibrosis (MF), and anemia of chronic kidney disease (CKD), and DISC-3405 (formerly MWTX-003) for the treatment of polycythemia vera (PV) and other hematologic disorders. In addition, its preclinical programs also include DISC-0998, for the treatment of anemia associated with inflammatory diseases. Bitopertin is the lead product candidate in the Company's heme biosynthesis modulation portfolio. It is developing DISC-3405, a monoclonal antibody against Transmembrane Serine Protease 6 that it licensed from Mabwell Therapeutics, Inc.

Disc Medicine Inc简介



公司代码IRON

公司名称Disc Medicine Inc

上市日期Aug 12, 2020

CEOQuisel (John D)

员工数量84

证券类型Ordinary Share

年结日Aug 12

公司地址321 Arsenal Street, Suite 101

城市WATERTOWN

上市交易所NASDAQ OMX - NASDAQ BASIC

国家United States of America

邮编02472

电话16176749274

网址https://www.discmedicine.com/

公司代码IRON

上市日期Aug 12, 2020

CEOQuisel (John D)

Disc Medicine Inc公司高管



名称

名称/职务

职务

持股

持股变动

Dr. Rahul Khara, Pharm.D.

Chief Legal Officer

36.87K

+162.73%

Ms. Pamela Stephenson

Chief Commercial Officer

6.03K

-91.33%

Mr. Jonathan Yu

Chief Operating Officer

Mr. William White, J.D.

Independent Director

Dr. Donald W. (Don) Nicholson, Ph.D.

Executive Chairman of the Board

Dr. Liam T. Ratcliffe, M.D., Ph.D.

Independent Director

Ms. Jean M. Franchi, CPA

Chief Financial Officer

-100.00%

Dr. William Savage, M.D., Ph.D.

Chief Medical Officer

Dr. Georges Gemayel, Ph.D.

Director

Mr. Kevin J. Bitterman, Ph.D.

Independent Director

名称

名称/职务

职务

持股

持股变动

Dr. Rahul Khara, Pharm.D.

Chief Legal Officer

36.87K

+162.73%

Ms. Pamela Stephenson

Chief Commercial Officer

6.03K

-91.33%

Mr. Jonathan Yu

Chief Operating Officer

Mr. William White, J.D.

Independent Director

Dr. Donald W. (Don) Nicholson, Ph.D.

Executive Chairman of the Board

Dr. Liam T. Ratcliffe, M.D., Ph.D.

Independent Director

收入明细

由于公司未披露，未能获取相关数据

由于公司未披露，未能获取相关数据

业务

地区

由于公司未披露，未能获取相关数据

股东统计

更新时间: 11月16日周日

持股股东

股东类型

持股股东

占比

Fidelity Management & Research Company LLC

10.43%

Access Industries, Inc.

7.46%

BlackRock Institutional Trust Company, N.A.

4.49%

RA Capital Management, LP

4.18%

Atlas Venture

4.01%

其他

69.43%

持股股东

占比

Fidelity Management & Research Company LLC

10.43%

Access Industries, Inc.

7.46%

BlackRock Institutional Trust Company, N.A.

4.49%

RA Capital Management, LP

4.18%

Atlas Venture

4.01%

其他

69.43%

股东类型

持股股东

占比

Investment Advisor

38.73%

Investment Advisor/Hedge Fund

16.51%

Hedge Fund

15.63%

Venture Capital

9.99%

Private Equity

8.55%

Corporation

7.46%

Research Firm

2.13%

Sovereign Wealth Fund

0.76%

Individual Investor

0.43%

机构持股



更新时间: 10月1日周三

报告期

机构数

持股数

持股占比

持股变动

2025Q3

341

35.08M

92.93%

-3.22M

2025Q2

344

37.34M

107.82%

+1.72M

2025Q1

342

37.53M

108.38%

+1.77M

2024Q4

318

30.70M

90.70%

-5.11M

2024Q3

302

32.06M

106.93%

-4.30M

2024Q2

292

32.17M

107.84%

+2.52M

2024Q1

275

26.60M

108.28%

-1.06M

2023Q4

248

24.37M

101.48%

-1.80M

2023Q3

211

23.78M

99.79%

-259.52K

2023Q2

190

22.86M

100.53%

+3.93M

股东持股明细



名称

持股数

占比

持股变动

变动比例

公告日期

Fidelity Management & Research Company LLC

3.08M

8.87%

+31.14K

+1.02%

Jun 30, 2025

Access Industries, Inc.

3.56M

10.24%

Feb 27, 2025

BlackRock Institutional Trust Company, N.A.

1.71M

4.93%

-38.49K

-2.20%

Jun 30, 2025

RA Capital Management, LP

1.58M

4.54%

Jun 30, 2025

Atlas Venture

2.15M

6.18%

-235.47K

-9.88%

Aug 14, 2025

The Vanguard Group, Inc.

1.39M

+90.73K

+6.98%

Jun 30, 2025

Frazier Life Sciences Management, L.P.

1.65M

4.76%

-100.00K

-5.70%

Jun 30, 2025

OrbiMed Advisors, LLC

1.42M

4.07%

Jun 30, 2025

Wellington Management Company, LLP

1.43M

4.12%

-911.41K

-38.89%

Jun 30, 2025

T. Rowe Price Associates, Inc.

1.49M

4.3%

+155.07K

+11.58%

Jun 30, 2025

持股ETF



更新时间: 12月6日周六

机构名称

占比

ALPS Medical Breakthroughs ETF

1.25%

Virtus LifeSci Biotech Clinical Trials ETF

1.11%

JPMorgan Healthcare Leaders ETF

0.92%

State Street SPDR S&P Biotech ETF

0.79%

Direxion Daily S&P Biotech Bull 3X Shares

0.48%

JPMorgan Fundamental Data Science Small Core ETF

0.4%

ProShares Ultra Nasdaq Biotechnology

0.39%

Invesco Nasdaq Biotechnology ETF

0.29%

iShares Health Innovation Active ETF

0.27%

iShares Biotechnology ETF

0.18%

ALPS Medical Breakthroughs ETF

占比1.25%

Virtus LifeSci Biotech Clinical Trials ETF

占比1.11%

JPMorgan Healthcare Leaders ETF

占比0.92%

State Street SPDR S&P Biotech ETF

占比0.79%

Direxion Daily S&P Biotech Bull 3X Shares

占比0.48%

JPMorgan Fundamental Data Science Small Core ETF

占比0.4%

ProShares Ultra Nasdaq Biotechnology

占比0.39%

Invesco Nasdaq Biotechnology ETF

占比0.29%

iShares Health Innovation Active ETF

占比0.27%

iShares Biotechnology ETF

占比0.18%

分红派息



近5年累计派现 0.00 美元

公告日期

分红计划

股权登记日

现金发放日

除权除息日

暂无数据

拆合股



公告日期

类型

比率

Dec 29, 2022

Merger

10→1

Dec 29, 2022

Merger

10→1

Dec 29, 2022

Merger

10→1

Dec 29, 2022

Merger

10→1

公告日期

类型

比率

Dec 29, 2022

Merger

10→1

Dec 29, 2022

Merger

10→1

Dec 29, 2022

Merger

10→1

Dec 29, 2022

Merger

10→1

常见问题

Disc Medicine Inc的前五大股东是谁？



Disc Medicine Inc 的前五大股东如下：
Fidelity Management & Research Company LLC持有股份：3.08M，占总股份比例：8.87%。
Access Industries, Inc.持有股份：3.56M，占总股份比例：10.24%。
BlackRock Institutional Trust Company, N.A.持有股份：1.71M，占总股份比例：4.93%。
RA Capital Management, LP持有股份：1.58M，占总股份比例：4.54%。
Atlas Venture持有股份：2.15M，占总股份比例：6.18%。